The Standard Concentration of Morphine as a Positive Control for Intradermal Skin Test
This study has been completed.
Information provided by:
First received: February 27, 2009
Last updated: February 16, 2011
Last verified: February 2011
This study aims to compare skin reactivity results between morphine and histamine as a positive control agents in intradermal skin test.
||Observational Model: Cohort
Time Perspective: Cross-Sectional
||The Standard Concentration of Morphine as a Positive Control for Intradermal Skin Test
Primary Outcome Measures:
- Wheal diameter from morphine skin test at different concentrations compared to standard histamine between 15-30 minutes after skin test [ Time Frame: 30 minutes ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Side effects [ Time Frame: 24 hours ] [ Designated as safety issue: Yes ]
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||October 2009 (Final data collection date for primary outcome measure)
Histamine hydrochloride and different concentrations of morphine sulfate will be intradermally injected and wheal diameter size will be comparatively measured between 15-30 minutes' time points after the test.
|Ages Eligible for Study:
||18 Years to 60 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- immunodeficiency state
- severe skin diseases
- severe medical illnesses
- uncontrolled asthma
- received oral or systemic corticosteroid within 1 month before this study
- receiving immunosuppressive agents
- taken antihistamine within 3 days before this study
- taking beta-blocker
- previous history of immunotherapy
- have hypersensitivity reaction to morphine/opiates
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00853476
|Faculty of Medicine, Chulalongkorn University
|Bangkok, Thailand, 10330 |
||Jettanong Klaewsongkram, MD
No publications provided
ClinicalTrials.gov processed this record on March 26, 2015
||Jettanong Klaewsongkram, MD, Chulalongkorn University
History of Changes
|Other Study ID Numbers:
|Study First Received:
||February 27, 2009
||February 16, 2011
||Thailand: Ethical Committee